{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:22:20Z","timestamp":1793262140192,"version":"4.5.0"},"reference-count":51,"publisher":"European Respiratory Society (ERS)","issue":"2","license":[{"start":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T00:00:00Z","timestamp":1666828800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","award":["Unrestricted grant"],"award-info":[{"award-number":["Unrestricted grant"]}],"id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Interreg \u00d6resund-Kattegat-Skagerrak","award":["NYPS20201002"],"award-info":[{"award-number":["NYPS20201002"]}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["Unrestricted grant"],"award-info":[{"award-number":["Unrestricted grant"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2022,9,30]]},"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Type 2 (T2) high asthma is recognised as a heterogenous entity consisting of several endotypes; however, the prevalence and distribution of the T2 biomarkers in the general asthma population, across asthma severity, and across compartments is largely unknown. The objective of the present study was to describe expression and overlaps of airway and systemic T2 biomarkers in a clinically representative asthma population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients with asthma from the real-life BREATHE cohort referred to a specialist centre were included and grouped according to T2 biomarkers: blood and sputum eosinophilia (\u22650.3\u00d710<jats:sup>9<\/jats:sup>\u2005cells\u00b7L<jats:sup>\u22121<\/jats:sup>and 3% respectively), total IgE (\u2265150\u2005U\u00b7mL<jats:sup>\u22121<\/jats:sup>), and fractional exhaled nitric oxide (\u226525 ppb).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Patients with mild-to-moderate asthma were younger (41<jats:italic>versus<\/jats:italic>49 years, p&lt;0.001), had lower body mass index (25.9<jats:italic>versus<\/jats:italic>28.0\u2005kg\u00b7m<jats:sup>\u22122<\/jats:sup>, p=0.002) and less atopy (47%<jats:italic>versus<\/jats:italic>58%, p=0.05), higher forced expiratory volume in 1\u2005s (3.2<jats:italic>versus<\/jats:italic>2.8\u2005L, p&lt;0.001) and forced vital capacity (4.3<jats:italic>versus<\/jats:italic>3.9\u2005L, p&lt;0.001) compared with patients with severe asthma, who had higher blood (0.22\u00d710<jats:sup>9<\/jats:sup><jats:italic>versus<\/jats:italic>0.17\u00d710<jats:sup>9<\/jats:sup>\u2005cells\u00b7L<jats:sup>\u22121<\/jats:sup>, p=0.01) and sputum (3.0%<jats:italic>versus<\/jats:italic>1.5%, p=0.01) eosinophils. Co-expression of all T2 biomarkers was a particular characteristic of severe asthma (p&lt;0.001). In patients with eosinophilia, sputum eosinophilia without blood eosinophilia was present in 45% of patients with mild-to-moderate asthma and 35% with severe asthma.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Severe asthma is more commonly associated with activation of several T2 pathways, indicating that treatments targeting severe asthma may need to act more broadly on T2 inflammatory pathways. Implementation of airway inflammometry in clinical care is of paramount importance, as the best treatable trait is otherwise is overlooked in a large proportion of patients irrespective of disease severity.<\/jats:p><\/jats:sec>","DOI":"10.1183\/23120541.00483-2022","type":"journal-article","created":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T14:35:42Z","timestamp":1666881342000},"page":"00483-2022","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Distribution of type 2 biomarkers and association with severity, clinical characteristics and comorbidities in the BREATHE real-life asthma population"],"prefix":"10.1183","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8488-3741","authenticated-orcid":false,"given":"Laurits","family":"Fr\u00f8ssing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1068-6723","authenticated-orcid":false,"given":"Ditte K.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7995-2965","authenticated-orcid":false,"given":"Morten","family":"Hvidtfeldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4926-5897","authenticated-orcid":false,"given":"Nicolai","family":"Obling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1391-7446","authenticated-orcid":false,"given":"Gunilla","family":"Telg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6716-3010","authenticated-orcid":false,"given":"Jonas S.","family":"Erjef\u00e4lt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1231-9209","authenticated-orcid":false,"given":"Uffe","family":"Bodtger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4825-9436","authenticated-orcid":false,"given":"Celeste","family":"Porsbjerg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2022,10,27]]},"reference":[{"key":"2024101711440908000_9.2.00483-2022.1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/ni.3049","article-title":"The immunology of asthma","volume":"16","author":"Lambrecht","year":"2014","journal-title":"Nat Immunol"},{"key":"2024101711440908000_9.2.00483-2022.2","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/cea.13966","article-title":"Airway gene expression identifies subtypes of type 2 inflammation in severe asthma","volume":"52","author":"Fr\u00f8ssing","year":"2022","journal-title":"Clin Exp Allergy"},{"key":"2024101711440908000_9.2.00483-2022.3","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.jaip.2020.09.051","article-title":"The prevalence of subtypes of type 2 inflammation in an unselected population of patients with severe asthma","volume":"9","author":"Fr\u00f8ssing","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2024101711440908000_9.2.00483-2022.4","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jaip.2017.06.015","article-title":"Subphenotypes of type 2 severe asthma in adults","volume":"6","author":"Matsusaka","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2024101711440908000_9.2.00483-2022.5","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201103-0396OC"},{"key":"2024101711440908000_9.2.00483-2022.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808991"},{"key":"2024101711440908000_9.2.00483-2022.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403290"},{"key":"2024101711440908000_9.2.00483-2022.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.05.020"},{"key":"2024101711440908000_9.2.00483-2022.9","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S2213-2600(21)00226-5","article-title":"Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"9","author":"Diver","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2024101711440908000_9.2.00483-2022.10","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201208-1414OC"},{"key":"2024101711440908000_9.2.00483-2022.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804092"},{"key":"2024101711440908000_9.2.00483-2022.12","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2003.014894"},{"key":"2024101711440908000_9.2.00483-2022.13","doi-asserted-by":"publisher","DOI":"10.2174\/1568010054526359"},{"key":"2024101711440908000_9.2.00483-2022.14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2008.02969.x"},{"key":"2024101711440908000_9.2.00483-2022.15","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00634-2017"},{"key":"2024101711440908000_9.2.00483-2022.16","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/MCP.0000000000000536","article-title":"Unravelling the complexity of tissue inflammation in uncontrolled and severe asthma","volume":"25","author":"Erjef\u00e4lt","year":"2019","journal-title":"Curr Opin Pulm Med"},{"key":"2024101711440908000_9.2.00483-2022.17","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00201813"},{"key":"2024101711440908000_9.2.00483-2022.18","doi-asserted-by":"crossref","first-page":"1736934","DOI":"10.1080\/20018525.2020.1736934","article-title":"Clinical characteristics of the BREATHE cohort \u2013 a real-life study on patients with asthma and COPD","volume":"7","author":"Backer","year":"2020","journal-title":"Eur Clin Respir J"},{"key":"2024101711440908000_9.2.00483-2022.19","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00202013"},{"key":"2024101711440908000_9.2.00483-2022.20","doi-asserted-by":"publisher","DOI":"10.1159\/000330667"},{"key":"2024101711440908000_9.2.00483-2022.21","doi-asserted-by":"publisher","DOI":"10.1177\/1479972315576144"},{"key":"2024101711440908000_9.2.00483-2022.22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1843.2006.00784.x"},{"key":"2024101711440908000_9.2.00483-2022.23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31324-1"},{"key":"2024101711440908000_9.2.00483-2022.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2014.02.005"},{"key":"2024101711440908000_9.2.00483-2022.25","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.9120-11ST"},{"key":"2024101711440908000_9.2.00483-2022.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804093"},{"key":"2024101711440908000_9.2.00483-2022.27","first-page":"CD003559","article-title":"Omalizumab for asthma in adults and children","volume":"1","author":"Normansell","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2024101711440908000_9.2.00483-2022.28","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jaip.2019.11.020","article-title":"Diagnosis and management of T2-high asthma","volume":"8","author":"Coverstone","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2024101711440908000_9.2.00483-2022.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2006.11.639"},{"key":"2024101711440908000_9.2.00483-2022.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.08.048"},{"key":"2024101711440908000_9.2.00483-2022.31","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13601-018-0201-3","article-title":"Having concomitant asthma phenotypes is common and independently relates to poor lung function in NHANES 2007\u20132012","volume":"8","author":"Amaral","year":"2018","journal-title":"Clin Transl Allergy"},{"key":"2024101711440908000_9.2.00483-2022.32","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/cea.13137","article-title":"Simultaneously elevated","volume":"48","author":"Mogensen","year":"2018","journal-title":"Clin Exp Allergy"},{"key":"2024101711440908000_9.2.00483-2022.33","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13601-019-0282-7","article-title":"Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations","volume":"9","author":"Price","year":"2019","journal-title":"Clin Transl Allergy"},{"key":"2024101711440908000_9.2.00483-2022.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.06.007"},{"key":"2024101711440908000_9.2.00483-2022.35","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/j.jaci.2016.01.044","article-title":"Simultaneously increased fraction of exhaled nitric oxide levels and blood eosinophil counts relate to increased asthma morbidity","volume":"138","author":"Malinovschi","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"2024101711440908000_9.2.00483-2022.36","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.rmed.2017.12.001","article-title":"A retrospective cohort study in severe asthma describing commonly measured biomarkers: eosinophil count and IgE levels","volume":"134","author":"Haughney","year":"2018","journal-title":"Respir Med"},{"key":"2024101711440908000_9.2.00483-2022.37","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201109-1640OC"},{"key":"2024101711440908000_9.2.00483-2022.38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1814917"},{"key":"2024101711440908000_9.2.00483-2022.39","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2009.126722"},{"key":"2024101711440908000_9.2.00483-2022.40","doi-asserted-by":"crossref","unstructured":"Corren J , Du E , Gubbi A , et al . Variability in blood eosinophil counts in patients with eosinophilic asthma. J Allergy Clin Immunol Pract 202; 9: 1224\u20131231.","DOI":"10.1016\/j.jaip.2020.10.033"},{"key":"2024101711440908000_9.2.00483-2022.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2010.08.028"},{"key":"2024101711440908000_9.2.00483-2022.42","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60988-X"},{"key":"2024101711440908000_9.2.00483-2022.43","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201903-0599LE"},{"key":"2024101711440908000_9.2.00483-2022.44","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S2213-2600(15)00050-8","article-title":"Diagnostic accuracy of minimally invasive markers for detection of airway eosinophilia in asthma: a systematic review and meta-analysis","volume":"3","author":"Korevaar","year":"2015","journal-title":"Lancet Respir Med"},{"key":"2024101711440908000_9.2.00483-2022.45","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00260-2020"},{"key":"2024101711440908000_9.2.00483-2022.46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704064"},{"key":"2024101711440908000_9.2.00483-2022.47","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N Engl J Med"},{"key":"2024101711440908000_9.2.00483-2022.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2003.08.014"},{"key":"2024101711440908000_9.2.00483-2022.49","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/resp.14294","article-title":"Sub-stratification of type-2 high airway disease for therapeutic decision-making: a \u2018bomb\u2019 (blood eosinophils) meets \u2018magnet\u2019 (F eNO) framework","volume":"27","author":"Couillard","year":"2022","journal-title":"Respirology"},{"key":"2024101711440908000_9.2.00483-2022.50","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00280-2019"},{"key":"2024101711440908000_9.2.00483-2022.51","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.chest.2021.04.013","article-title":"Eosinophilic and noneosinophilic asthma: an expert consensus framework to characterize phenotypes in a global real-life severe asthma cohort","volume":"160","author":"Heaney","year":"2021","journal-title":"Chest"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.00483-2022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T05:21:42Z","timestamp":1740374502000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.00483-2022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,27]]},"references-count":51,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,3,20]]},"published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1183\/23120541.00483-2022"],"URL":"https:\/\/doi.org\/10.1183\/23120541.00483-2022","relation":{},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,27]]}}}